Composition can include a nucleoside polymerase inhibitor of hepatitis C viral or one of its pharmaceutically acceptable salts or prodrugs, an inhibitor of hepatitis C viral protease or its pharmaceutically acceptable salts or prodrugs and not nucle u00f3s polymerase inhibitor Gone viral hepatitis C or its pharmaceutically acceptable salts or prodrugs.Methods for treating a Pathological condition such as an infection by the hepatitis C virus, hepatic Fibrosis and / or impaired hepatic function with a nucleoside polymerase inhibitor of hepatitis C viral or its pharmaceutically acceptable salts or prodrugs,A protease inhibitor of hepatitis C viral or its pharmaceutically acceptable salts or prodrugs and non nucleoside polymerase inhibitor of hepatitis C viral or its pharmaceutically acceptable salts or prodrugs.Claim 1: Composition characterized in that it comprises a First Compound or its pharmaceutically acceptable salts or prodrugs, where the first Compound is a compound of formula (1)； a Second Compound or its pharmaceutically acceptable salts or prodrugs,Where the second rest is a compound of formula (2)； and a Third Compound or its pharmaceutically acceptable salts or prodrugs, where the rest is a Third Compound of formula (3). Claim 7: the composition according to claim 2, wherein the one or more additional therapeutic agents are Ribavirin and ritonavir.Composición que puede incluir un inhibidor de polimerasa nucleósido de hepatitis C viral o una de sus sales o profármacos farmacéuticamente aceptables, un inhibidor de proteasa de hepatitis C viral o sus sales o profármacos farmacéuticamente aceptables y un inhibidor de polimerasa no nucleósido de hepatitis C viral o sus sales o profármacos farmacéuticamente aceptables. Métodos para tratar una condición patológica tales como una infección por virus de hepatitis C, fibrosis hepática y/o función hepática alterada con un inhibidor de polimerasa nucleósido de hepatitis C viral o sus sales o profármacos farmacéutica
